ArticleScientific reports2026
Diagnostic performance of antigen test for the detection of SARS-CoV-2 among patients presenting with COVID-19 symptoms at Bugando Medical Centre.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global public health threat causing Coronavirus Disease-2019 (COVID-19). The World Health Organization approved reverse transcriptase polymerase chain reaction (RT-PCR) as a gold standard for the detection of SARS-CoV-2. RT-PCR requires high technology and well-trained personnel, hindering its applicability in low-health care facilities. We evaluated the diagnostic performance of an antigen rapid diagnostic test (Ag-RDT) in detecting SARS-CoV-2 infection among patients presenting with COVID-19 symptoms at Bugando Medical Centre in Mwanza, Tanzania. This laboratory-based cross-sectional study involving 503 COVID-19 suspects was conducted in Mwanza between May 2022 and August 2022. The samples were tested by the RT-PCR and RADI COVID-19 Ag-RDT. Of 98 (20%) samples tested positive for both RT-PCR and Ag-RDT, 379 (75%) tested negative for both RT-PCR. The overall diagnostic performance of Ag-RDT showed 79.0% sensitivity and 100% specificity. During the early stage of cough with fever (≤ 4 days), Ag-RDT showed a high sensitivity of 86.1%. Ag-RDT can be used with much confidence in screening for SARS-CoV-2 infection in individuals presenting with a combination of cough and fever within the first four days of infection and cough was significantly associated with a positive Ag-RDT (p = 0.008).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.